2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Scientific Sessions

The Role of Epigenetics in Cancer Diagnosis

This session focuses on the crucial role of epigenetic changes, such as DNA methylation and histone modifications, in the development and progression of cancer. Key epigenetic biomarkers, such as BRCA1 methylation in breast cancer, are emerging as powerful tools for early detection, enabling more accurate diagnoses and improved patient outcomes. At the Cancer Research and Development Conference 2025, this scientific session will delve into the growing potential of epigenetic biomarkers for early detection, prognosis, and treatment monitoring. In addition, epigenetic therapies, including epigenetic reprogramming, are being developed as promising strategies for personalized cancer care. Join us at this groundbreaking event in 2025 to explore the exciting advancements in epigenetic-driven cancer therapies and their potential to revolutionize cancer care.

Related Sessions

Current Landscape and Future Directions of Oncology Research
Oncogenic Signaling Pathways and Therapeutic Targets
Emerging Biomarkers for Cancer Detection and Prognosis
Cancer Prevention and Early Detection Strategies
Immuno Oncology and Cell Based Therapies
Innovations in Immuno Oncology
Cytokine Modulation and Immune Adjuvants in Cancer Immunotherapy
Cancer Vaccines
CAR T Cell Therapy: Clinical Progress and Challenges
Next Generation Cell and Gene Therapies in Oncology
Liquid Biopsy and Circulating Tumor DNA (ctDNA) Diagnostics
Companion Diagnostics
Artificial Intelligence and Machine Learning in Precision Oncology
Next Generation Targeted Therapies: KRAS, HER2, BRAF, and NRAS
Overcoming Drug Resistance: Mechanisms and Solutions
Oncology Pipeline
Trends in Antibody Drug Conjugates (ADCs)
Launch of Novel mAb Products for Cancer Therapy